FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
1.86B
2.28B
2.45B
2.29B
2.51B
2.74B
3B
3.28B
3.59B
3.92B
Revenue %
-
22.94
7.43
-6.53
9.46
9.34
9.34
9.34
9.34
Ebitda
425.59M
581.86M
598.9M
-598.89M
575.55M
382.08M
417.75M
456.75M
499.4M
546.02M
Ebitda %
22.91
25.48
24.41
-26.12
22.93
13.92
13.92
13.92
13.92
Ebit
318.44M
419.94M
438.46M
-754M
420.32M
204.54M
223.64M
244.52M
267.35M
292.31M
Ebit %
17.14
18.39
17.87
-32.88
16.75
7.45
7.45
7.45
7.45
Depreciation
107.16M
161.92M
160.43M
155.1M
155.23M
177.54M
194.11M
212.23M
232.05M
253.71M
Depreciation %
5.77
7.09
6.54
6.76
6.18
6.47
6.47
6.47
6.47
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
